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The aim of this study was to examine the possible adverse drug-drug interactions in the elderly population 
(≥60 years) diagnosed either with diabetes, arterial hypertension or both, at a Family Health Unit (FHU) 
clinic in Blumenau, state of Santa Catarina, Brazil. For this purpose 318 subjects were interviewed using 
a pretested form with social and demographic aspects regarding their disease and its complications. 
All drugs used by this population were grouped, and the drug-drug interactions were detected by using 
the “Drug Interaction Checker” software, and classified for frequency and severity. The average age 
of patients was 70.6 years, with a higher number of female patients (216; 67.9%). Most subjects were 
being treated for both diseases (149; 46.86%). Out of a total of 1,541 medications prescribed, the most 
prevalent were: hydrochlorothiazide (131; 8.4%) and enalapril maleate (130; 8.4%). A total of 295 
possible drug-drug interactions were detected in 152 patients (1.9 interactions per subject), 275 (93.2%) 
moderate and 20 (6.8%) severe or highly severe. The possible interaction prevalence was 0.93 (0.55 to 
1.40 depending on health unit). The most frequent possible interaction was that between acetylsalicylic 
acid and enalapril maleate (37; 12.5%). Patients had an average consumption of 6.6 drugs and 9.8% of 
subjects reported physical discomfort when using medicines. Elderly patients use many medications 
that could cause adverse reactions and possible drug-drug interactions, where this issue warrants closer 
attention of prescribers and health providers.
Uniterms: Drug-drug interaction. Systemic arterial hypertension/use of medications. Diabetes Mellitus/
use of medications. Elderly/use of medications. Family health program.
Buscou-se identificar possíveis interações medicamentosas em pessoas idosas com diabetes melito 
(DM) e/ou hipertensão arterial sistêmica (HAS) sendo atendidas em unidades de Saúde da Família, em 
Blumenau (SC). Entrevistaram-se 318 pessoas com 60 e mais anos, portadoras de DM e/ou HAS, mediante 
questionário estruturado pré-testado, com variáveis sócio-demográficas da doença e do tratamento. 
As interações medicamentosas foram verificadas através do aplicativo “Drug Interaction Checker” 
e classificadas quanto a freqüência e severidade. A maioria dos pacientes era do sexo feminino (216; 
67,9%), com média de idade de 70,6 anos (DP = 6,9), recebendo tratamento por ambas as doenças (149; 
46,86%). Dentre 1.541 medicamentos prescritos, os mais prevalentes foram: hidroclorotiazida (131; 8,4%) 
e maleato de enalapril (130; 8,4%). Foram detectadas 295 possíveis interações medicamentosas em 152 
idosos (média 1,9 interações), das quais (275; 93,2%) foram moderadas e (20; 6,8%) severas ou muito 
severas. A prevalência de possíveis interações foi de 0,93 (0,55 a 1,40, dependendo da unidade de saúde). 
A possível interação mais freqüente foi entre ácido acetilsalicílico e maleato de enalapril (37; 12,5%). 
Cada paciente fazia uso de 6,6 medicamentos em média e 9,8% relataram algum desconforto físico com 
o uso de medicamentos. Idosos utilizam grande quantidade de medicamentos que resultam em reações 
adversas e possíveis interações medicamentosas, merecendo maior atenção dos prescritores e gestores.
Unitermos: Interação medicamentosa. Hipertensão arterial sistêmica/uso de medicamentos. Diabetes 
melito/uso de medicamentos. Idosos/uso de medicamentos. Saúde da família.
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INTRODUCTION
Weight gain in the Western population as a whole, 
together with inadequate feeding habits, physical inacti-
vity, and the use of tobacco and alcohol, have contributed 
to an increase in the prevalence of health problems such 
as arterial hypertension and diabetes (Ogden et al.., 2006).
In the presence of this unbalanced way of life, phy-
sicians are facing a great challenge: providing adequate 
therapeutic support to patients with interrelated and even 
synergistic diseases. These resultant drug combinations 
can decrease the overall treatment efficacy and/or favor ad-
verse reactions of varying degrees of severity. The strategy 
to treat coexisting pathologies results in polypharmacy 
(use of five or more drugs), a situation that could be exa-
cerbated by the consumption of over-the-counter (OTC) 
remedies (Junius-Walker et al., 2007). 
With the increased life expectancy in Brazil, the 
at-risk population for development of diverse age-related 
diseases has grown. As a result, clinicians are faced with 
a growing number of patients who are evidently fragile 
to deal with invasive treatments and interventions. Thus, 
polypharmacy appears to be a problem in this sub-po-
pulation. In a review, Rozenfeld (2003) pointed out that 
Brazilian epidemiological studies show that medicine use 
increases with age, and around 80% of aged people con-
sume at least one medicine regularly while 30% of elderly 
consume over-the-counter (OTC) medicines. Medical 
prescriptions in this group commonly evidence inadequate 
doses and indications, unexpected pharmacological inte-
ractions and unsuitable medication associations, besides 
the use of therapeutically ineffective medications.
The treatment of patients with arterial hypertension 
and/or diabetes is no exception regarding polypharmacy. 
When patients are diagnosed with arterial hypertension 
and/or diabetes, many different medications could be 
appropriate for their treatment, including drugs for dysli-
pidemia, hypertension, antiplatelet therapy and glycemic 
control (Triplitt, 2006).
The identification of drug-drug interactions in pa-
tients with hypertension and/or diabetes could be very 
important, because these diseases are highly prevalent in 
Brazil. The treatment of these diseases includes highly 
complex therapeutics, which are undergoing rapid deve-
lopment and employ substances that are relatively new in 
the market, whose interactions are not yet fully clarified, 
or documented. A significant proportion of these new 
drugs are available on the Brazilian public health system 
(Brasil, 2009).
The extent of suffering and deaths caused directly 
by pharmacological interactions is not clear, but cur-
rent evidence shows that this problem deserves serious 
attention on the part of both the medical community 
and the population who self-medicate and disregard the 
risks involved (Lima, 2004). Currently, an increasing 
number of people have access to a host of medications 
(thanks to large number of medication providers, such as 
physicians, pharmacists, friends and relatives), and their 
utilization can become abusive, particularly with regard 
to the risk for undesirable pharmacological interactions 
among chronically diseased patients (Lima, 2004; Ro-
zenfeld, 2003).
Results from different studies on adverse drug 
reactions (ADRs) have been pooled in some meta-
analyses, showing that the proportion of drug-related 
hospitalization is between 2.4 and 6.2% where many such 
cases were preventable (Cresweel et al., 2007). Another 
prospective observational study in England found that 
adverse drug reactions cost £466 million annually, resul-
ting in the deaths of around 5700 patients (Pirmohamed 
et al., 2004). 
The aim of the present study was to verify the 
possible pharmacological interactions in elderly arterial 
hypertension and/or diabetes patients attended at Family 
Health Strategy units of Blumenau, in the state of Santa 
Catarina, Brazil.
MATERIAL AND METHODS
This is a cross-sectional epidemiologic study on a 
sample population composed of elderly people with arte-
rial hypertension and/or diabetes, living and registered in 
the area covered by the Family Health Strategy (FHS), in 
the city of Blumenau, state of Santa Catarina (SC), Brazil.
Elderly persons were considered individuals, aged 
60 or older, as proposed by WHO for developing countries 
(Brasil, 2006).
Individuals with at least six months of clinical 
follow-up, and living in areas covered by FHS units in 
place for at least 1 year before the field work started in 
2006 April, were included in the study. 
Two-stage random sampling took place. In the first 
stage, a simple random sampling of 10 Family Health units 
was carried out (of the 34 existing units that had been in 
operation for more than 1 year). In the second sampling 
stage, those people living in the area covered by the units 
and registered as arterial hypertensive and/or diabetic were 
identified. Subsequently, stratified random sampling was 
done, distributing the sample size proportionally for peo-
ple with arterial hypertension and/or diabetes registered in 
every unit. Thus, the people aged 60 years or more were 
identified and included in this study.
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The study participants were visited at home and a 
pretested questionnaire was applied by trained and qua-
lified interviewers. Data on the following variables were 
obtained: sex, age (average value and age ranges), mari-
tal status (if married, single, widow, or separated), race/
color (as reported by the interviewee), religion practiced, 
educational level (collected as completed years of study 
and categorized as 1st to 4th elementary school, 5th - 8th 
middle school, and complete high school or graduated), 
current consumption of tobacco and alcohol (type and 
quantity), time of diagnosis (in months), time of treatment 
(in months), other associated diseases, name and amount 
of consumed medications, use of natural homemade re-
medies, presence of any physical discomfort when using 
medication.
In order to estimate the presence of drug-drug in-
teractions, the medications consumed by every person 
in the last 7 days were identified. These medications 
were entered into an on-line software program (Drug 
Interaction Checker), which performed a bibliographical 
search of three (3) databases: the U.S. Food and Drug 
Administration (FDA), American Hospital Formulary 
Service (AHFS Drug Information) and First DataBank, 
generating a report containing the following information: 
1) Presence of interaction: whether any type of interac-
tion is occurring or not; 2) Severity: any interaction being 
classified as ‘very severe’ (drug combination is contra-
indicated and should not be dispensed or administered 
to patient); ‘severe’ action is required to decrease the 
interaction risk); and ‘moderate’ (interaction risk should 
be evaluated and action measures are also necessary); 
3)Symptoms and clinical signs and; 4) Mechanism of 
action.
Consumed medications were organized according 
to the Brazilian Common Denomination, which assigns 
the name of active principles utilized by pharmaceutical 
industry through the Ordinance # 1179, dated June 17th, 
1996.
The data were descriptively presented in tables by 
frequencies with a confidence interval of 95%. For the con-
tinuous variables, the central trend (mean and median) and 
dispersion (standard deviation) measures were calculated. 
The prevalence (number of events divided by persons at 
risk) of possible interactions was also calculated.
This present study was developed with data col-
lected by the Project “Adherence to pharmacological 
treatment of patients with hypertension and/or diabetes 
mellitus in the family health units in Blumenau (SC)”, 
previously approved by the Institutional Review Board/
Independent Ethics Committee of the Regional University 
of Blumenau (040/2004).
RESULTS
Three hundred and eighteen individuals aged 60 
years or older with arterial hypertension and/or diabetes, 
were interviewed.
These people were predominantly female (216; 
67.9%), had a mean age of 70.6 years (standard deviation 
of 6.9 years) and median age of 69.9 years. The majority 
of these people had studied only up to 1st – 4th years of 
elementary school (210; 66.2%) or were illiterate (75; 
23.7%) (Table1).
With respect to lifestyle, 29 people affirmed to be 
smokers (9.1%, 95% CI 6.2 – 12.8) and 264 reported not 
to be in use of any type of alcoholic beverage (83.0%, 95% 
CI 78.4 – 87.0). The most consumed type of beverage (by 
32 persons) was beer (10.1%, 95% CI 7.0 – 13.9).
Table 2 shows information on diseases and medi-
cations. 
The average treatment time of patients with arterial 
hypertension was 162.3 months (SD = 144.7) and median 
was 120 months. The average time for treatment of dia-
betes was 115.3 months (SD = 96.6) and the median was 
84 months.
Out of a total of 1541 prescribed medications, the 
four most frequent medications were: hydrochlorothiazide 
(131; 8.4%), enalapril maleate (130; 8.4%), lovastatin 
(100; 6.5%) and metformin (97; 6.3%) (Table 3). Patients 
were in use of, on average, 4.8 medications.
The presence of 295 possible drug-drug interactions 
in 152 elderly people (47.8%; n= 318) was detected. Out of 
these possible interactions, 275 were of moderate severity 
(93.2%), 19 were severe (6.5%) and 1 was very severe 
(0.3%). The prevalence of possible interactions was 0.93, 
(0.55 to 1.40 depending on the family health unit). 
The most frequent medications in the interactions 
were acetylsalicylic acid (85; 14.3%), enalapril maleate 
(75; 12.6%), glibenclamide (71; 12.0%) and digoxin (51; 
8.6%). 
As shown in Table 5, the most frequent potential 
drug-drug interactions were between: acetylsalicylic acid 
and enalapril maleate (37; 12.5%) glibenclamide and 
hydrochlorothiazide (33; 11.1%), acetylsalicylic acid 
and glibenclamide (22; 7.4%) and enalapril maleate and 
furosemide (21; 7.1%).
Twenty possible interactions were detected with a 
higher grade of severity. One of these was considered very 
severe and occurred with nortriptyline hydrochloride and 
selegiline. This drug-drug interaction can lead to a severe 
reaction, including the symptoms: hyperpyrexia, convul-
sions, excitability, muscle stiffness, fluctuations in blood 
pressure, epilepsy, coma, and death.
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Out of 19 pharmacological interactions considered 
severe, the most frequent were: bromazepam and fluoxeti-
ne hydrochloride (3; 1.0%), amiodarone hydrochloride and 
digoxin (3; 1.0%), metformin and norfloxacin (2; 0.7%), 
amiodarone hydrochloride and sodium warfarin (2; 0.7%) 
and glibenclamide and norfloxacin (2; 0.7%).
The clinical manifestations and mechanism of action 
of more severe pharmacological interactions are shown 
in Table VI.
It is noteworthy that in one individual, 11 possible 
drug-drug interactions were detected, 3 being severe and 8 
moderate. The severe interactions comprised: amiodarone 
hydrochloride and digoxin; amiodarone hydrochloride 
and sodium warfarin; sulfasalazine and sodium warfarin.
Out of 318 interviewees, 60 (18.9%) reported 
spontaneously physical discomfort when utilizing some 
type of medication. Given that a person could complain 
about more than one discomfort, there was a total of 75 
complaints for the 60 patients. Out of these, 17(22.6%) 
complaints were of stomach pain, 9 (12.0%) nauseas, 7 
(9.3%) dizziness, 4 (5.4%) weakness, 4 (5.4%) shortness 
of breath, 3 (4.0%) diarrhea. The other symptoms amoun-
ted to a total of 31 complaints (41.3%).
TABLE I - Socio-demographic variables
Variables Frequency (N)
Relative Freq. 
(95% CI)
Sex     Female
           Male
216
102
67.9
(62.5 – 73.0) 
32.1
(27.0 – 37.5)
Age range   
 60-70 160 50.3 44.7 – 55.9
 70-80 126 39.6 34.2 – 45.2
 80 or older 32 10.1 7.0 – 13.9
Marital Status   
 Married/Stable Union 153 48.2 42.5 – 53.8
 Single 12 3.7 2.0 – 6.5
 Separated 29 9.2 6.2 – 12.8
 Widow 124 38.9 33.6 – 44.6
Color   
 White 270 84.9 80.5 – 88.7
 Brown 34 10.7 7.5 – 14.6
 Black 12 3.7 2.0 – 6.5
 Other 2 0.7 0.0 – 2.2
Religion*   
 Roman Catholic 243 76.8 71.9 – 81.4
 Protestant/Evangelic 57 18.1 14.0 – 22.7
 Spiritist 1 0.3 0.0 – 1.8
 Other 13 4.1 2.2 – 6.9
 None 2 0.7 0.0 – 2.2
Educational level*
 Illiterate 75 23.7 19.1 – 28.7
 1st – 4th years – elementary 210 66.2 60.7 – 71.4
 5th – 8th years – middle 25 7.9 5.2 – 11.4
 Complete High School or graduated 7 2.2 0.9 – 4.5
(*) Excluding unknown cases.
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TABLE II - Treatment
Variables Frequency (N) Relative Freq. 95% Confidence Interval
Disease undergoing Treatment   
Hypertension 146 45.9 40.3 – 51.6
Diabetes mellitus 23 7.2 4.6 – 10.7
Both 149 46.9 41.3 – 52.5
Time of Treatment Hypertension*   
< 1 year 15 5.2 2.9 – 8.4
1 - 5 years 74 25.4 20.5 – 30.8
5 - 10 years 68 23.4 18.6 – 28.7
10 - 20 years 88 30.2 25.0 – 35.9
> 20 years 46 15.8 11.8 – 20.5
Time of Treatment Diabetes Mellitus 
< 1 year 15 8.9 5.1 – 14.3
1 - 5 years 50 29.8 23.0 – 37.3
5 - 10 years 50 29.8 23.0 – 37.3
10 - 20 years 37 22.0 16.0 – 29.1
> 20 years 16 9.5 5.5 – 15.0
Number of Medications*   
0 7 2.3 0.9 – 4.6
1 to 4 164 53.4 47.7 – 59.1
5 to 8 119 38.8 33.3 – 44.5
9 to 13 16 5.2 3.0 – 8.3
21 1 0.3 0.0 – 1.8
Use of Natural Homemade  Remedies*   
Yes 144 46.0 40.4 – 51.7
No 168 53.7 48.0 – 59.3
Not Informed 1 0.3 0.0 – 1.8
(*) Excluding unknown cases.
TABLE III - Medications consumed (n= 1541)
Variables Frequency (N) Relative Freq. 95% Confidence Interval
Hydrochlorothiazide 131 8.4 7.2 – 10.0
Enalapril Maleate 130 8.4 7.2 – 10.0
Lovastatin 100 6.5 5.3 – 7.8
Metformin 97 6.3 5.1 – 7.6
Acetylsalicylic Acid 87 5.6 4.5 – 6.9
Glibenclamide 87 5.6 4.5 – 6.9
Atenolol 59 3.8 2.9 – 4.9
Captopril 51 3.3 2.5 – 4.3
Omeprazole 42 2.7 2.0 – 3.7
Propranolol Hydrochloride 33 2.1 1.5 – 3.0
Furosemide 33 2.1 1.5 – 3.0
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DISCUSSION
The sample studied has shown similarities with the 
populations studied in other national (Marin et al., 2008; 
Meireles et al.,2007; Paniz et al., 2008; Zaitune et al., 2007; 
Silva et al., 2006) and international (Lawson et al., 2006; 
Dubova et al., 2007; Bjorkman et al., 2002) investigations 
involving elderly attended in the primary care system. 
Potential drug-drug interactions were detected in 
152 out of the 318 elderly interviewed (47.7%). This 
frequency is lower than the figure reported in a Mexican 
study, where almost 80% of patients presented potential 
pharmacologic interactions. This difference could be as-
sociated to the Mexican study’s inclusion criteria, namely, 
patients older than 50 years, with non-malignant algic syn-
drome. It is noteworthy that the prevalence of hyperten-
TABLE IV - Most frequent medications in interactions (n=590)
Variables Frequency (N) Relative Freq. 95% Confidence Interval
Acetylsalicylic Acid 85 14.3 11.7 – 17.5
Enalapril Maleate 75 12.6 10.1 – 15.7
Glibenclamide 71 12.0 9.5 – 14.9
Digoxin 51 8.6 6.5 – 11.2
Furosemide 46 7.8 5.8 – 10.3
Hydrochlorothiazide 46 7.8 5.8 – 10.3
Captopril 28 4.7 3.2 – 6.9
Spironolactone 27 4.5 3.0 – 6.6
Lovastatin 21 3.5 2.2 – 5.4
Sodium Warfarin 12 2.0 1.1 – 3.5
TABLE V - Most frequent potential drug-drug interactions and their clinical effects
Variable N (%) 95%Confidence 
Interval
Clinical effect
Acetylsalicylic Acid + Enalapril Maleate 37 (12.5) 8.9 – 16.9 Decreased Antihypertensive effect
Glibenclamide + Hydrochlorothiazide 33 (11.1)  7.8 – 15.4 Decreased Antihypertensive effect; 
Worse Glucose tolerance
Acetylsalicylic Acid + Glibenclamide 22 (7.4) 4.7 – 11.1 Reinforced Hypoglycemic effect 
Enalapril Maleate + Furosemide 21 (7.1) 4.5 – 10.7 Postural hypotension
Acetylsalicylic Acid + Captopril 15 (5.1) 2.9 – 8.2 Decreased Antihypertensive effect
Spironolactone + Enalapril Maleate 11 (3.7) 1.9 – 6.6 Hyperkalemia
Digoxin + Spironolactone 10 (3.4) 1.6 – 6.1 Digoxin toxicity symptoms (anorexia, 
nauseas, vomits, headache, fatigue, 
disorientation,  hallucination and 
arrhythmia)
Digoxin + Hydrochlorothiazide 10 (3.4) 1.6 – 6.1 Digoxin toxicity symptoms (anorexia, 
nauseas, vomits, headache, fatigue, 
disorientation,  hallucination and 
arrhythmia)
Digoxin + Lovastatin 9 (3.0) 1.4 – 5.7 Increased rhabdomyolysis risk
Captopril + Furosemide 7 (2.4) 1.0 – 4.8 Postural hypotension
Propranolol Hydrochloride + Glibenclamide 7 (2.4) 1.0 – 4.8 Decreased responses to insulin and 
sulphonylureas; Potentially increased 
frequency and severity of hypoglycemia 
episodes
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sive and diabetic patients was higher in the present study 
(67.3% and 29.5%, respectively), as were the predominant 
interactions, generally associated to medications used to 
treat these pathologies (Dubova et al., 2007). 
In addition, another European multicenter study 
conducted in 5 countries involving individuals aged 65 
years or older in use of 4 medications or more, detected 
some type of possible interaction in 46% of the sample 
(Bjorkman et al., 2002).
With respect to tobacco use, the vast majority, 90.9% 
of those interviewed, stated they were non-smokers. Stu-
dies have shown that the percentage of smokers declines 
proportionally with age (Paniz et al.., 2008; Sawatzky et 
al.., 2007; Dubova et al., 2007). In a comparative study of 
TABLE VI - Clinical manifestations and mechanism of action of most severe potential drug-drug interactions
Severe interactions Clinical manifestation Mechanism of action
Bromazepam
Fluoxetine Hydrochloride
Increased BZD levels;
Clinical effect increased BZD.
Certain SSRIs (Selective Serotonin 
Reuptake Inhibitors) could decrease the 
Phase I metabolism of BZD through the 
competitive inhibition of CYP-450.
Amiodarone Hydrochloride
Digoxin
Digoxin toxicity symptoms (anorexia, nauseas, 
vomits, headache, fatigue, disorientation, 
hallucination and arrhythmia) 
Multiple mechanisms appear to be involved. 
Amiodarone decreases the renal and non-
renal clearance of digitalis glycosides (DG), 
decreases the volume of distribution and 
increases the bioequivalence of DG. Also, 
DG depressed the sinus node, producing 
bradycardia.
Metformin
Norfloxacin
Deep Hypoglycemia Unknown 
Amiodarone Hydrochloride
Sodium Warfarin
Bleeding risk. The amiodarone has been shown to inhibit 
the metabolism of R and S enantiomers of 
Warfarin by CYP-450. It could also inhibit 
the metabolism of acenocoumarol and other 
anticoagulants.
Glibenclamide
Norfloxacin/Cinofloxacin
Deep Hypoglycemia. Unknown 
Phenprocoumon
Sodium Levothyroxine
Hypothyroidism could increase oral 
anticoagulant requirement.
The administration of thyroid hormones or 
hyperthyroidism could decrease the oral 
anticoagulant requirement.
Unknown 
Atenolol
Clonidine Hydrochloride
Severe Hypertension. b-Blockers inhibit the vasodilatation 
mediated by b2-receptor, decreasing the 
opposition to vasoconstriction mediated by 
a2-receptor.
Sodium Warfarin
Sulfasalazine
Bleeding risk;
Decreased Prothrombin activity.
Unknown 
Sodium Warfarin 
Sodium Levothyroxine
Hypothyroidism could increase the oral 
anticoagulant requirement.
The administration of thyroid hormones or 
hyperthyroidism could decrease the oral 
anticoagulant requirement.
Unknown 
Diazepam
Fluoxetine Hydrochloride
Increased  BZD levels;
Clinical effect increase of BZD.
Certain SSRIs (Selective Serotonin 
Reuptake Inhibitors) could decrease the 
Phase I metabolism of BZD through 
competitive inhibition of CYP-450.
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smoking prevalence, a higher decline in total percentage 
of smoking elderly individuals was evident from 1989 
until 2003 where in 2003 a percentage of 14% of elderly 
smokers was found in the sample (Monteiro et al., 2007).
In this study, 60 persons (18.9%) reported physical 
discomfort with the use of some medication, with stoma-
ch pain (12%) and nausea (9.3%) being the predominant 
complaints. The inadequate use of medications in elderly 
has been high in many studies, with some symptoms being 
connected with specific drugs. In the study of Gurwitz et 
al.. (2003) there was association of dry mouth with the use 
of antidepressive medications and nauseas with digoxin 
and NSAIDs. According to Dubova et al.. (2007), cardio-
vascular disease allied to polypharmacy (>5 drugs) and 
advanced age (>60 years), are risk factors for drug-drug 
interactions.
The most consumed medication was hydrochloro-
thiazide (8.4%) followed by enalapril maleate (8.4%), 
lovastatin (6.5%), metformin (6.3%), acetylsalicylic acid 
(5.6%), glibenclamide (5.6%) and atenolol (3.8%). Given 
this, with the exception of metformin and omeprazole, 
the 10 most-prescribed medications were associated with 
58% of cases of possible interactions. The predominance 
of drugs affecting the cardiovascular system, pancreas and 
endocrine system and drugs utilized in homeostasis and 
thrombosis was also evidenced in a Brazilian study with 
elderly individuals, irrespective of the disease (Marin et 
al., 2008).
The most frequent potential drug-drug interactions 
include acetylsalicylic acid with enalapril maleate or gli-
benclamide, but most patients use acetylsalicylic acid in 
low doses (80 to 200mg) to prevent major cardiovascular 
events, thereby lowering the risk of interactions. Out of 
295 possible drug-drug interactions, 20 (6.8%) were consi-
dered severe or very severe and included the most frequen-
tly prescribed medications (metformin, glibenclamide and 
atenolol). The use of norfloxacin it notable because, when 
associated to metformin (2 occurrences) or glibenclamide 
(2 occurrences) norfloxacin can cause deep hypoglycemia 
by an as yet unknown mechanism. Norfloxacin should also 
be prescribed with caution in elderly when associated to 
steroids because of the risk of tendon ruptures. The use 
of trimethoprim-sulfamethoxazole (in patients utilizing 
metformin) or cephalexin (in those using glibenclamide) 
could represent alternatives.
Also, it is important to consider the patient’s renal 
function and manage this risk. The use of atenolol com-
bined with clonidine (1 occurrence) could lead to severe 
hypertension by blockage of B2 receptors, annulling 
the balance with vasoconstriction mediated by alpha 
receptors. An alternative to this prescription could be the 
combination of atenolol with enalapril maleate (Mion et 
al., 2002).
Digoxin was the fourth medication in the list of main 
causers of pharmacological interactions, and was related 
to 13.8% of pharmacological interactions, despite being 
present in only 1.6% of prescriptions. Due to its narrow 
therapeutic window (0.8 to 2.0 ng/mL) and reduced renal 
function in elderly patients, there is a higher chance of 
toxicity. Its association with amiodarone represents 1% of 
interactions and is considered severe, causing effects of 
digitalis intoxication. It is a drug considered inappropriate, 
but of low risk by the Beers criterion for elderly, at doses 
above 0.125mg/dose, even after taking into account the 
presence of other drugs for cardiac failure (inhibitors of an-
giotensin conversion enzyme, betablockers and diuretics) 
and for arrhythmias (amiodarone) (Packer et al., 1993; 
Fick et al., 2003; Fialová et al., 2005; Chutka et al.., 2004).
Many studies are evaluating the use of electronic 
means to help healthcare professionals in the identifi-
cation of possible pharmacological interactions in their 
prescriptions. The possibility of reducing pharmacological 
interactions using such devices is a current focus of study. 
However, many difficulties have been pointed out in the 
use of such systems, including the main issue of the lack 
of specificity in results, with too many interactions being 
indicated, few of which are actually relevant. Other pro-
blems include the lack of emphasis in warnings for the 
more severe interactions, leading to many people ignoring 
or underestimating the warnings issued by these computer 
programs (Tamblin et al., 2003; Ahearn, Stephen, 2003).
Limitations
This study presents some limitations. There are 
several definitions of elderly and most of these can be 
criticized because they are based on age alone. Although 
the WHO recommends 60 years and older for developing 
countries, many authors around the world have adopted 
55 or 65 years. It is important to bear in mind that being 
elderly does not only refer to age alone, but to a special 
phase in life, all of which are related to particular condi-
tions (social, clinical, emotional) that must be taken into 
account when comparisons are made
There are different software programs supported 
by a variety of databases which identify possible drug-
drug interactions. This array of options could explain the 
frequency of discrepancies found among studies. In this 
study, an open web database was used to facilitate access 
and achieve better comparisons.
It is worth mentioning that cross-sectional studies 
such as the present investigation, can only detect preva-
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lent cases of interactions. In severe cases, it is likely that 
patients with symptoms complain to their doctors or ask to 
change medicines. Therefore, some cases can only be de-
tected in longitudinal investigations such as cohort studies.
CONCLUSIONS
Access to medications was broadened following im-
plementation of the Family Health Strategy, particularly to 
drugs requested for hypertension and diabetes (Paniz et al., 
2008). However, the high proportion of possible drug-drug 
interactions and adverse reactions suggest that measures 
should be taken in order to improve the quality of care, by 
means of continued education for prescribers, as well as 
by improvement of dispensation conditions in these units 
(usually done by nursing staff). The frequent staff turnover 
of family health teams, compromising sustained continuity 
of care, associated to treatment that is sometimes given by 
different medical specialists, could also contribute to the 
occurrence of possible interactions. Further investigations 
should be undertaken to evaluate the consistency of the 
results obtained and to study their possible determinants.
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